204 related articles for article (PubMed ID: 27707590)
1. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma.
Gerami P; Yao Z; Polsky D; Jansen B; Busam K; Ho J; Martini M; Ferris LK
J Am Acad Dermatol; 2017 Jan; 76(1):114-120.e2. PubMed ID: 27707590
[TBL] [Abstract][Full Text] [Related]
2. Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy.
Ferris LK; Jansen B; Ho J; Busam KJ; Gross K; Hansen DD; Alsobrook JP; Yao Z; Peck GL; Gerami P
JAMA Dermatol; 2017 Jul; 153(7):675-680. PubMed ID: 28445578
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Analysis Differentiates Melanomas from Spitz Nevi.
Jansen B; Hansen D; Moy R; Hanhan M; Yao Z
J Drugs Dermatol; 2018 May; 17(5):574-576. PubMed ID: 29742191
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin.
Gerami P; Alsobrook JP; Palmer TJ; Robin HS
J Am Acad Dermatol; 2014 Aug; 71(2):237-44. PubMed ID: 24906614
[TBL] [Abstract][Full Text] [Related]
5. Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions.
Ferris LK; Gerami P; Skelsey MK; Peck G; Hren C; Gorman C; Frumento T; Siegel DM
Melanoma Res; 2018 Oct; 28(5):478-482. PubMed ID: 30004988
[TBL] [Abstract][Full Text] [Related]
6. Analytical Characteristics of a Noninvasive Gene Expression Assay for Pigmented Skin Lesions.
Yao Z; Allen T; Oakley M; Samons C; Garrison D; Jansen B
Assay Drug Dev Technol; 2016 Aug; 14(6):355-63. PubMed ID: 27505074
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma.
Ferris LK; Moy RL; Gerami P; Sligh JE; Jansen B; Yao Z; Cockerell CJ
J Invest Dermatol; 2019 May; 139(5):1127-1134. PubMed ID: 30500343
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in situ hybridization (FISH) analysis of melanocytic nevi and melanomas: sensitivity, specificity, and lack of association with sentinel node status.
Fang Y; Dusza S; Jhanwar S; Busam KJ
Int J Surg Pathol; 2012 Oct; 20(5):434-40. PubMed ID: 22561674
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
10. Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors.
Al-Rohil RN; Curry JL; Torres-Cabala CA; Nagarajan P; Ivan D; Aung PP; Lyons GF; Bassett RL; Prieto VG; Tetzlaff MT
Hum Pathol; 2016 Jul; 53():73-81. PubMed ID: 27004944
[TBL] [Abstract][Full Text] [Related]
11. Dermoscopic features associated with 3-GEP PLA: LINC00518, PRAME, and TERT expression in suspicious pigmented lesions.
Ludzik J; Becker AL; Latour E; Lee C; Witkowski A
Skin Res Technol; 2023 Apr; 29(4):e13323. PubMed ID: 37083005
[TBL] [Abstract][Full Text] [Related]
12. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.
Clarke LE; Warf MB; Flake DD; Hartman AR; Tahan S; Shea CR; Gerami P; Messina J; Florell SR; Wenstrup RJ; Rushton K; Roundy KM; Rock C; Roa B; Kolquist KA; Gutin A; Billings S; Leachman S
J Cutan Pathol; 2015 Apr; 42(4):244-52. PubMed ID: 25727210
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.
See SHC; Finkelman BS; Yeldandi AV
Pathol Res Pract; 2020 Sep; 216(9):153105. PubMed ID: 32825968
[TBL] [Abstract][Full Text] [Related]
14. Progress in melanoma histopathology and diagnosis.
Piris A; Mihm MC
Hematol Oncol Clin North Am; 2009 Jun; 23(3):467-80, viii. PubMed ID: 19464597
[TBL] [Abstract][Full Text] [Related]
15. Non-Invasive Gene Expression Testing to Rule Out Melanoma.
Rivers JK; Copley MR; Svoboda R; Rigel DS
Skin Therapy Lett; 2018 Sep; 23(5):1-4. PubMed ID: 30248161
[TBL] [Abstract][Full Text] [Related]
16. Melanoma antigen-encoding gene expression in melanocytic naevi and cutaneous malignant melanomas.
Basarab T; Picard JK; Simpson E; Russell-Jones R
Br J Dermatol; 1999 Jan; 140(1):106-8. PubMed ID: 10215777
[TBL] [Abstract][Full Text] [Related]
17. Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome.
Greene MH; Clark WH; Tucker MA; Elder DE; Kraemer KH; Guerry D; Witmer WK; Thompson J; Matozzo I; Fraser MC
N Engl J Med; 1985 Jan; 312(2):91-7. PubMed ID: 3964923
[No Abstract] [Full Text] [Related]
18. Detection of cutaneous malignant melanoma by tape stripping of pigmented skin lesions - A systematic review.
Thomsen IMN; Heerfordt IM; Karmisholt KE; Mogensen M
Skin Res Technol; 2023 Mar; 29(3):e13286. PubMed ID: 36973976
[TBL] [Abstract][Full Text] [Related]
19. Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
Magro CM; Abraham RM; Guo R; Li S; Wang X; Proper S; Crowson AN; Mihm M
Eur J Dermatol; 2014; 24(5):594-602. PubMed ID: 25118781
[TBL] [Abstract][Full Text] [Related]
20. Dermatoscopy versus Tzanck smear test: a comparison of the value of two tests in the diagnosis of pigmented skin lesions.
Durdu M; Baba M; Seçkin D
J Am Acad Dermatol; 2011 Nov; 65(5):972-82. PubMed ID: 21565420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
